AnaptysBio (ANAB) PT Lowered to $146 at Wedbush

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to AnaptysBio (ANAB) PT Lowered to $146 at Wedbush

AnaptysBio Announces Third Quarter 2018 Financial Results and Provides Pipeline Updates

November 8, 2018 4:15 PM EST

Reported positive top-line data from an interim analysis of its ongoing Phase 2a proof-of-concept clinical trial of etokimab in severe eosinophilic asthmaInitiated Phase 2 ECLIPSE trial of etokimab in chronic rhinosinusitis with nasal polyps and Phase 2 POPLAR trial of ANB019 in palmo-plantar pustulosisFour top-line clinical efficacy readouts from wholly-owned pipeline anticipated in 2019

SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the third quarter ended... More